Samuëlsz, Errin
3Cardiff Oncology Inc., San Diego, California.
2 papers on CoChatORCID 0000-0002-3424-7330
Most cited papers
- Verified
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 49
- Verified
436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
Ahn, D. H., Erlander, M., Ridinger, M., Samuëlsz, E., Barzi, A., Bekaii-Saab, T., & Lenz, H. J. (2020) · Annals of Oncology
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free